Business
Trevi Therapeutics to Participate in Upcoming March Investor Conferences
NEW HAVEN, Conn., Feb. 27, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"NEW HAVEN, Conn., Feb. 27, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending the following investor conferences in March.\n\n \n \n \n \n \n \n\n \nTD Cowen 45th Annual Health Care ConferenceMarch 3-5, 2025, Boston, MassachusettsCorporate Presentation: March 4, 10:30-11:00am ETTrevi Representatives: Lisa Delfini, Chief Financial Officer, and Farrell Simon, Chief Commercial OfficerA Corporate presentation is available for in-person conference attendees.\nLeerink Partners Global Healthcare ConferenceMarch 10-12, 2025, Miami, FloridaCorporate Presentation: March 12, 8:00am ETTrevi Representatives: Jennifer Good, President and CEO, and James Cassella, Chief Development OfficerA Corporate presentation is available for in-person conference attendees.\nLeerink Partners Mountain MeetingMarch 23-26, 2025, Jackson Hole, WyomingTrevi Representative: Lisa Delfini, Chief Financial OfficerA Corporate presentation is available for in-person conference attendees.\nAbout Trevi Therapeutics, Inc.Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), which are opioid receptors that play a key role in controlling cough hypersensitivity. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. \nChronic cough is highly prevalent in IPF patients, impacting up to 85% of the IPF population. There are ~140,000 U.S. IPF patients and the impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved therapi...